Aurora kinase inhibitors as anti-cancer therapy

被引：55

作者：

Lok, Warren

Klein, Rhonda Q. ^{[2
]}

Saif, Muhammad Wasif ^{[1
]}

机构：

[1] Yale Univ, Sch Med, Yale Canc Ctr, Dept Med Oncol, New Haven, CT 06520 USA

[2] Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06520 USA

来源：

ANTI-CANCER DRUGS | 2010年 / 21卷 / 04期

关键词：

AT9283; aurora kinase inhibitors; AZD1152; ENMD-2076; MLN8237; PF03814735; PHA739358; SNS-314; VX680/MK0457; VX689/MK5108; CHROMOSOMAL PASSENGER PROTEIN; SPINDLE ASSEMBLY CHECKPOINT; CYCLE-DEPENDENT EXPRESSION; SMALL-MOLECULE INHIBITOR; B-KINASE; A KINASE; HISTONE H3; C KINASE; CENTROSOME AMPLIFICATION; DNA REREPLICATION;

D O I：

10.1097/CAD.0b013e3283350dd1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aurora kinases are serine and threonine kinases that function as key regulators of the mitosis process. There are three distint human aurora kinases known as Aurora A, Aurora B, and Aurora C. Aurora A and Aurora B are overexpressed in a number of human cancers including non-small cell lung cancer, glioblastomas, and upper gastrointestinal adenocarcinomas. Given their association with tumorigenesis, both Aurora A and Aurora B have been targeted for cancer therapy. Currently, a number of selective and nonselective aurora kinase inhibitors are being tested in preclinical and clinical settings as anti-tumor agents. We review the biology of human aurora kinases, followed by an overview of inhibitors undergoing current clinical investigations. Anti-Cancer Drugs 21: 339-350 (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.

引用

页码：339 / 350

页数：12

共 50 条

[1] The Aurora kinase inhibitors in cancer research and therapy
Jonas Cicenas
[J]. Journal of Cancer Research and Clinical Oncology, 2016, 142 : 1995 - 2012
[2] The Aurora kinase inhibitors in cancer research and therapy
Cicenas, Jonas
[J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2016, 142 (09) : 1995 - 2012
[3] Pyrazolopyridine-based kinase inhibitors for anti-cancer targeted therapy
Halder, Pallabi
Rai, Anubhav
Talukdar, Vishal
Das, Parthasarathi
Lakkaniga, Naga Rajiv
[J]. RSC MEDICINAL CHEMISTRY, 2024, 15 (05): : 1452 - 1470
[4] Photoactivation of inhibitors of anti-cancer therapy
Bodagh, Reta
Beharry, Andrew
[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 257
[5] Anti-cancer therapy with cyclin-dependent kinase inhibitors: impact and challenges
Reinius, Marika A. V.
Smyth, Elizabeth
[J]. EXPERT REVIEWS IN MOLECULAR MEDICINE, 2021, 23
[6] Small Molecule Kinase Inhibitors as Anti-Cancer Therapeutics
Chahrour, O.
Cairns, D.
Omran, Z.
[J]. MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2012, 12 (05) : 399 - 411
[7] Development of heparanase inhibitors for anti-cancer therapy
Miao, Hua-Quan
Liu, Hu
Navarro, Elizabeth
Kussie, Paul
Zhu, Zhenping
[J]. CURRENT MEDICINAL CHEMISTRY, 2006, 13 (18) : 2101 - 2111
[8] Aurora kinases as an anti-cancer target
Ikezoe, Takayuki
[J]. CANCER LETTERS, 2008, 262 (01) : 1 - 9
[9] HIF-1 inhibitors as anti-cancer therapy
MOORING Suazette Reid
[J]. Science China(Chemistry)., 2011, 54 (01) - 30
[10] CHECKPOINT INHIBITORS AS A FOUNDATION FOR ANTI-CANCER IMMUNE THERAPY
Sznol, Mario
[J]. ANNALS OF ONCOLOGY, 2014, 25

← 1 2 3 4 5 →